155 related articles for article (PubMed ID: 10955786)
1. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
[TBL] [Abstract][Full Text] [Related]
7. Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.
Zhang Z; Chen H; Chan KK; Budd T; Ganapathi R
J Chromatogr B Biomed Sci Appl; 1999 May; 728(1):85-95. PubMed ID: 10379660
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat.
Boon PJ; van der Boon D; Mulder GJ
Toxicol Appl Pharmacol; 2000 Aug; 167(1):55-62. PubMed ID: 10936079
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
de Lima DC; Rodrigues SV; Boaventura GT; Cho HY; Chen TC; Schönthal AH; Da Fonseca CO
Drug Test Anal; 2020 Feb; 12(2):268-279. PubMed ID: 31800149
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
16. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells.
Yeruva L; Pierre KJ; Elegbede A; Wang RC; Carper SW
Cancer Lett; 2007 Nov; 257(2):216-26. PubMed ID: 17888568
[TBL] [Abstract][Full Text] [Related]
17. R-Limonene metabolism in humans and metabolite kinetics after oral administration.
Schmidt L; Göen T
Arch Toxicol; 2017 Mar; 91(3):1175-1185. PubMed ID: 27325307
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
19. Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.
Garcia DG; de Castro-Faria-Neto HC; da Silva CI; de Souza e Souza KF; Gonçalves-de-Albuquerque CF; Silva AR; de Amorim LM; Freire AS; Santelli RE; Diniz LP; Gomes FC; Faria MV; Burth P
Mol Cancer; 2015 May; 14():105. PubMed ID: 25976744
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content.
Chow HH; Salazar D; Hakim IA
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1472-6. PubMed ID: 12433729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]